Search

Search Constraints

You searched for: Author/Creator Barbieri, Fausto

Search Results

11. Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation. Issue 2 (19th October 2020)

12. Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation. Issue 2 (19th October 2020)

13. Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation. Issue 2 (19th October 2020)

14. BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients: Results from a multicenter Italian observational study. (May 2016)

15. Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients. (February 2020)

16. Case Report - Squamous Cell Carcinoma "Transformation" Concurrent with Secondary T790M Mutation in Resistant EGFR-Mutated Adenocarcinomas. Issue 4 (April 2016)

17. Cytidine deaminase enzymatic activity is a prognostic biomarker in gemcitabine/platinum-treated advanced non-small-cell lung cancer: a prospective validation study. Issue 11 (27th November 2018)

18. Diamond: immunohistochemistry versus sequencing in EGFR analysis of lung adenocarcinomas. Issue 5 (9th November 2015)

19. Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy. Issue 4 (7th April 2021)

20. First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status. (May 2020)